ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2026 Nuclear Energy Conference & Expo (NECX)
August 24–27, 2026
Dallas, TX|Hilton Anatole
Latest Magazine Issues
Jun 2026
Jan 2026
2026
Latest Journal Issues
Nuclear Science and Engineering
July 2026
Nuclear Technology
June 2026
Fusion Science and Technology
May 2026
Latest News
MARVEL team shares lessons learned through microreactor development
On June 1 at the American Nuclear Society’s Annual Conference in Denver, Colo., a team from Idaho National Laboratory presented a session titled “Lessons Learned from MARVEL Reactor Fabrication.” The presentation highlighted challenges that arose as they moved from design to manufacturing and assembly, with a focus on reactor part fabrication, Stirling engine implementation, and reactivity control system development.
Victor R. Prybutok, Leonard M. Gold
Nuclear Technology | Volume 78 | Number 3 | September 1987 | Pages 303-311
Nuclear Power Plant Kalkar (SNR-300) | Nuclear Safety | doi.org/10.13182/NT87-A15996
Articles are hosted by Taylor and Francis Online.
The leukemia incidence risk for a single coal plant, a single nuclear plant, and a single nuclear accident is used to compute the total industry leukemia incidence risk. In the absence of a nuclear power plant accident, the leukemia incidence risk is normally lower for a nuclear industry than for a coal industry of equivalent size. The nuclear industry risk with accidents was compared to the coal industry risk for six proposed dose response curves. Simplifying assumptions about the negligible effect of the cell-killing term and the linear nature of the linear quadratic curve allowed derivation of risk models for the assumption of both linear and quadratic dose response. These derived models, representing leukemia incidence risk bounds, are used to estimate the total industry risk comparison. Evaluation of an accident’s impact on the leukemia incidence risk comparison is done with the risk bounds and compared to the risk evaluations calculated during all six dose response curves. The overlapping plot of the number of nuclear accidents required for equivalent industry environmental risks versus the accident fraction allows the conservative function to be defined.